Biology of Blood and Marrow Transplantation
Volume 14, Issue 1 , Pages 75-87 , January 2008

Donor Killer Immunoglobulin-Like Receptor (KIR) Genotype-Patient Cognate KIR Ligand Combination and Antithymocyte Globulin Preadministration Are Critical Factors in Outcome of HLA-C-KIR Ligand-Mismatched T Cell–Replete Unrelated Bone Marrow Transplantation

  • Toshio Yabe

      Affiliations

    • Japanese Red Cross Tokyo Metropolitan Blood Center, Tokyo, Japan
    • Corresponding Author InformationCorrespondence and reprint requests: Toshio Yabe, PhD, Japanese Red Cross Tokyo Metropolitan Blood Center, 2-1-67 Tatsumi, Koto-ku, Tokyo 135-8639, Japan; Tel: +81-3-5534-7546; Fax: +81-3-5534-7547.
    • ,
  • Keitaro Matsuo

      Affiliations

    • Aichi Cancer Center Research Institute, Division of Epidemiology and Prevention, Nagoya, Japan
    • ,
  • Kouyuki Hirayasu

      Affiliations

    • Japanese Red Cross Tokyo Metropolitan Blood Center, Tokyo, Japan
    • University of Tokyo, Department of Human Genetics, Tokyo, Japan
    • ,
  • Koichi Kashiwase

      Affiliations

    • Japanese Red Cross Tokyo Metropolitan Blood Center, Tokyo, Japan
    • ,
  • Sumiyo Kawamura-Ishii

      Affiliations

    • Japanese Red Cross Central Blood Institute, Tokyo, Japan
    • ,
  • Hidenori Tanaka

      Affiliations

    • Japanese Red Cross Tokyo Metropolitan Blood Center, Tokyo, Japan
    • ,
  • Atsuko Ogawa

      Affiliations

    • Japanese Red Cross Tokyo Metropolitan Blood Center, Tokyo, Japan
    • ,
  • Minoko Takanashi

      Affiliations

    • Japanese Red Cross Tokyo Metropolitan Blood Center, Tokyo, Japan
    • ,
  • Masahiro Satake

      Affiliations

    • Japanese Red Cross Tokyo Metropolitan Blood Center, Tokyo, Japan
    • ,
  • Kazunori Nakajima

      Affiliations

    • Japanese Red Cross Tokyo Metropolitan Blood Center, Tokyo, Japan
    • ,
  • Katsushi Tokunaga

      Affiliations

    • University of Tokyo, Department of Human Genetics, Tokyo, Japan
    • ,
  • Hidetoshi Inoko

      Affiliations

    • Tokai University School of Medicine, Division of Molecular Science, Isehara, Japan
    • ,
  • Hiroo Saji

      Affiliations

    • HLA Laboratory, NPO, Kyoto, Japan
    • ,
  • Seishi Ogawa

      Affiliations

    • Tokyo University Hospital, Tokyo, Japan
    • ,
  • Takeo Juji

      Affiliations

    • Japanese Red Cross Central Blood Institute, Tokyo, Japan
    • ,
  • Takehiko Sasazuki

      Affiliations

    • International Medical Center of Japan, Tokyo, Japan
    • ,
  • Yoshihisa Kodera

      Affiliations

    • Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
    • ,
  • Yasuo Morishima

      Affiliations

    • Aichi Cancer Center Hospital, Department of Hematology and Cell Therapy, Nagoya, Japan
    • ,
  • Japan Marrow Donor Program

Received 18 July 2007 ,Accepted 21 September 2007.

References 

  1. Ruggeri L, Aversa F, Martelli MF, et al. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev. 2006;214:202–218
  2. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–2100
  3. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172:644–650
  4. Witt CS, Christiansen FT. The relevance of natural killer cell human leucocyte antigen epitopes and killer cell immunoglobulin-like receptors in bone marrow transplantation. Vox Sang. 2006;90:10–20
  5. Morishima Y, Yabe T, Matsuo K, et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell–replete marrow from an unrelated donor. Biol Blood Marrow Transplant. 2007;13:315–328
  6. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood. 2002;100:3825–3827
  7. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102:814–819
  8. Bornhauser M, Schwerdtfeger R, Martin H, et al. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood. 2004;103:2860–2862
  9. Schaffer M, Malmberg KJ, Ringden O, et al. Increased infection-related mortality in KIR ligand–mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation. 2004;78:1081–1085
  10. De Santis D, Bishara A, Witt CS, et al. Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. Tissue Antigens. 2005;65:519–528
  11. Hsu KC, Gooley T, Malkki M, et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant. 2006;12:828–836
  12. Farag SS, Bacigalupo A, Eapen M, et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biol Blood Marrow Transplant. 2006;12:876–884
  13. Sun JY, Dagis A, Gaidulis L, et al. Detrimental effect of natural killer cell alloreactivity in T cell–replete hematopoietic cell transplantation (HCT) for leukemia patients. Biol Blood Marrow Transplant. 2007;13:197–205
  14. Sivula J, Volin L, Porkka K, et al. Killer-cell immunoglobulin-like receptor ligand compatibility in the outcome of Finnish unrelated donor hematopoietic stem cell transplantation. Transpl Immunol. 2007;18:62–66
  15. Cook MA, Milligan DW, Fegan CD, et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood. 2004;103:1521–1526
  16. Cook M, Briggs D, Craddock C, et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell–replete stem cell transplantation. Blood. 2006;107:1230–1232
  17. Chen C, Busson M, Rocha V, et al. Activating KIR genes are associated with CMV reactivation and survival after non–T-cell–depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant. 2006;38:437–444
  18. Verheyden S, Schots R, Duquet W, et al. A defined donor-activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia. 2005;19:1446–1451
  19. McQueen KL, Dorighi KM, Guethlein LA, et al. Donor–recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol. 2007;68:309–323
  20. Clausen J, Wolf D, Petzer AL, et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol. 2007;148:520–528
  21. Sobecks RM, Ball EJ, Maciejewski JP, et al. Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors. Bone Marrow Transplant. 2007;39:417–424
  22. Zhao XY, Huang XJ, Liu KY, et al. Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients. Eur J Haematol. 2007;78:338–346
  23. Giebel S, Nowak I, Wojnar J, et al. Impact of activating killer immunoglobulin-like receptor genotype on outcome of unrelated donor-hematopoietic cell transplantation. Transplant Proc. 2006;38:287–291
  24. Sun JY, Gaidulis L, Dagis A, et al. Killer Ig-like receptor (KIR) compatibility plays a role in the prevalence of acute GVHD in unrelated hematopoietic cell transplants for AML. Bone Marrow Transplant. 2005;36:525–530
  25. Gagne K, Brizard G, Gueglio B, et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol. 2002;63:271–280
  26. Kroger N, Binder T, Zabelina T, et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell–depleted unrelated stem cell transplantation. Transplantation. 2006;82:1024–1030
  27. La Nasa G, Littera R, Locatelli F, et al. Status of donor–recipient HLA class I ligands and not the KIR genotype is predictive for the outcome of unrelated hematopoietic stem cell transplantation in beta-thalassemia patients. Biol Blood Marrow Transplant. 2007;in press
  28. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft-versus-host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant. 2005;35:225–231
  29. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med. 1998;339:1177–1185
  30. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A–, HLA-B–, and HLA-DR–matched unrelated donors. Blood. 2002;99:4200–4206
  31. Gomez-Lozano N, Vilches C. Genotyping of human killer-cell immunoglobulin-like receptor genes by polymerase chain reaction with sequence-specific primers: an update. Tissue Antigens. 2002;59:184–193
  32. Miyashita R, Tsuchiya N, Yabe T, et al. Association of killer cell immunoglobulin-like receptor genotypes with microscopic polyangiitis. Arthritis Rheum. 2006;54:992–997
  33. Yawata M, Yawata N, McQueen KL, et al. Predominance of group A KIR haplotypes in Japanese associated with diverse NK cell repertoires of KIR expression. Immunogenetics. 2002;54:543–550
  34. Yawata M, Yawata N, Draghi M, et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med. 2006;203:633–645
  35. Moretta A, Sivori S, Ponte M, et al. Stimulatory receptors in NK and T cells. Curr Top Microbiol Immunol. 1998;230:15–23
  36. Chewning JH, Gudme CN, Hsu KC, et al. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol. 2007;179:854–868
  37. Bishara A, De Santis D, Witt CC, et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens. 2004;63:204–211
  38. Giebel S, Locatelli F, Wojnar J, et al. Homozygosity for human leucocyte antigen-C ligands of KIR2DL1 is associated with increased risk of relapse after human leucocyte antigen C–matched unrelated donor haematopoietic stem cell transplantation. Br J Haematol. 2005;131:483–486
  39. Fischer JC, Ottinger H, Ferencik S, et al. Relevance of C1 and C2 epitopes for hemopoietic stem cell transplantation: role for sequential acquisition of HLA-C–specific inhibitory killer Ig-like receptor. J Immunol. 2007;178:3918–3923
  40. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105:4878–4884
  41. Miller JS, Cooley S, Parham P, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007;109:5058–5061
  42. Beelen DW, Ottinger HD, Ferencik S, et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood. 2005;105:2594–2600
  43. Ljunggren HG, Karre K. In search of the “missing self”: MHC molecules and NK cell recognition. Immunol Today. 1990;11:237–244
  44. Valiante NM, Uhrberg M, Shilling HG, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1997;7:739–751
  45. Han M, Fallena M, Guo Y, et al. Natural killer cell cross-match: functional analysis of inhibitory killer immunoglobulin-like receptors and their HLA ligands. Hum Immunol. 2007;68:507–513
  46. van der Slik AR, Koeleman BP, Verduijn W, et al. KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes. 2003;52:2639–2642
  47. Jones DC, Edgar RS, Ahmad T, et al. Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility. Genes Immun. 2006;7:576–582
  48. Yen JH, Moore BE, Nakajima T, et al. Major histocompatibility complex class I–recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med. 2001;193:1159–1167
  49. Mendez A, Granda H, Meenagh A, et al. Study of KIR genes in tuberculosis patients. Tissue Antigens. 2006;68:386–389
  50. Single RM, Martin MP, Gao X, et al. Global diversity and evidence for coevolution of KIR and HLA. Nat Genet. 2007;39:1114–1119
  51. Vales-Gomez M, Erskine RA, Deacon MP, et al. The role of zinc in the binding of killer cell Ig-like receptors to class I MHC proteins. Proc Natl Acad Sci U S A. 2001;98:1734–1739
  52. Saulquin X, Gastinel LN, Vivier E. Crystal structure of the human natural killer cell– activating receptor KIR2DS2 (CD158j). J Exp Med. 2003;197:933–938
  53. Stewart CA, Laugier-Anfossi F, Vely F, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A. 2005;102:13224–13229
  54. Biassoni R, Pessino A, Malaspina A, et al. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur J Immunol. 1997;27:3095–3099
  55. Maenaka K, Juji T, Nakayama T, et al. Killer cell immunoglobulin receptors and T cell receptors bind peptide major histocompatibility complex class I with distinct thermodynamic and kinetic properties. J Biol Chem. 1999;274:28329–28334
  56. Thananchai H, Gillespie G, Martin MP, et al. Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol. 2007;178:33–37
  57. Hansasuta P, Dong T, Thananchai H, et al. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol. 2004;34:1673–1679
  58. Vales-Gomez M, Reyburn HT, Erskine RA, et al. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J. 1999;18:4250–4260
  59. Carr WH, Rosen DB, Arase H, et al. Cutting edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J Immunol. 2007;178:647–651
  60. Winter CC, Gumperz JE, Parham P, et al. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol. 1998;161:571–577
  61. Lowe EJ, Turner V, Handgretinger R, et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell–depleted HLA-nonidentical paediatric bone marrow transplantation. Br J Haematol. 2003;123:323–326
  62. Savani BN, Mielke S, Adams S, et al. Rapid natural killer cell recovery determines outcome after T-cell–depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia. 2007;21:2145–2152
  63. Zhao XY, Huang XJ, Liu KY, et al. Reconstitution of natural killer cell receptor repertoires after unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation: analyses of CD94:NKG2A and killer immunoglobulin-like receptor expression and their associations with clinical outcome. Biol Blood Marrow Transplant. 2007;13:734–744
  64. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005;5:201–214

PII: S1083-8791(07)00489-2

doi: 10.1016/j.bbmt.2007.09.012

Biology of Blood and Marrow Transplantation
Volume 14, Issue 1 , Pages 75-87 , January 2008

Article Tools

* Image Usage & Resolution